MX2010007948A - Inhibidores de proteinas de apoptosis. - Google Patents
Inhibidores de proteinas de apoptosis.Info
- Publication number
- MX2010007948A MX2010007948A MX2010007948A MX2010007948A MX2010007948A MX 2010007948 A MX2010007948 A MX 2010007948A MX 2010007948 A MX2010007948 A MX 2010007948A MX 2010007948 A MX2010007948 A MX 2010007948A MX 2010007948 A MX2010007948 A MX 2010007948A
- Authority
- MX
- Mexico
- Prior art keywords
- present
- iap inhibitors
- apoptosis
- inhibitors
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2323708P | 2008-01-24 | 2008-01-24 | |
| PCT/US2009/031093 WO2009094287A1 (en) | 2008-01-24 | 2009-01-15 | Iap inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010007948A true MX2010007948A (es) | 2010-10-04 |
Family
ID=40901405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010007948A MX2010007948A (es) | 2008-01-24 | 2009-01-15 | Inhibidores de proteinas de apoptosis. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110288116A1 (OSRAM) |
| EP (1) | EP2242362A4 (OSRAM) |
| JP (1) | JP2011520770A (OSRAM) |
| KR (1) | KR20100119768A (OSRAM) |
| CN (1) | CN101951766A (OSRAM) |
| AU (1) | AU2009206588A1 (OSRAM) |
| BR (1) | BRPI0906785A2 (OSRAM) |
| CA (1) | CA2712604A1 (OSRAM) |
| IL (1) | IL207066A0 (OSRAM) |
| MX (1) | MX2010007948A (OSRAM) |
| WO (1) | WO2009094287A1 (OSRAM) |
| ZA (1) | ZA201005618B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| AR079528A1 (es) | 2009-12-18 | 2012-02-01 | Idenix Pharmaceuticals Inc | Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c |
| UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| WO2014022612A1 (en) * | 2012-08-01 | 2014-02-06 | Tetralogic Pharmaceuticals Corporation | Combination therapy |
| GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218862D0 (en) * | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
| ES2883289T3 (es) | 2013-12-20 | 2021-12-07 | Astex Therapeutics Ltd | Compuestos heterocíclicos bicíclicos y sus usos en terapia |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| ES2927195T3 (es) * | 2017-11-13 | 2022-11-03 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Miméticos de SMAC utilizados como inhibidores de IAP y uso de los mismos |
| US20220175917A1 (en) * | 2019-03-07 | 2022-06-09 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combination of iap inhibitor and immune checkpoint inhibitor |
| WO2020228642A1 (zh) * | 2019-05-10 | 2020-11-19 | 正大天晴药业集团股份有限公司 | 一种用作iap抑制剂的smac模拟物的结晶及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005069888A2 (en) * | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
| ME02125B (me) * | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitori protein apoptoze (iap) |
| US7674787B2 (en) * | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| EA012810B1 (ru) * | 2005-02-25 | 2009-12-30 | Тетралоджик Фармасеутикалс | Димерные ингибиторы ингибиторов белков апоптоза (iap) |
| US20070203749A1 (en) * | 2005-08-09 | 2007-08-30 | Sri Chunduru | Business methods for compounds for treatment of proliferative disorders |
-
2009
- 2009-01-15 KR KR1020107018102A patent/KR20100119768A/ko not_active Withdrawn
- 2009-01-15 EP EP09703244A patent/EP2242362A4/en not_active Withdrawn
- 2009-01-15 CN CN200980106206XA patent/CN101951766A/zh active Pending
- 2009-01-15 CA CA2712604A patent/CA2712604A1/en not_active Abandoned
- 2009-01-15 US US12/863,375 patent/US20110288116A1/en not_active Abandoned
- 2009-01-15 WO PCT/US2009/031093 patent/WO2009094287A1/en not_active Ceased
- 2009-01-15 JP JP2010544375A patent/JP2011520770A/ja not_active Abandoned
- 2009-01-15 MX MX2010007948A patent/MX2010007948A/es not_active Application Discontinuation
- 2009-01-15 AU AU2009206588A patent/AU2009206588A1/en not_active Abandoned
- 2009-01-15 BR BRPI0906785-0A patent/BRPI0906785A2/pt not_active IP Right Cessation
-
2010
- 2010-07-18 IL IL207066A patent/IL207066A0/en unknown
- 2010-08-05 ZA ZA2010/05618A patent/ZA201005618B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100119768A (ko) | 2010-11-10 |
| CN101951766A (zh) | 2011-01-19 |
| US20110288116A1 (en) | 2011-11-24 |
| EP2242362A4 (en) | 2012-04-11 |
| ZA201005618B (en) | 2011-04-28 |
| WO2009094287A1 (en) | 2009-07-30 |
| IL207066A0 (en) | 2010-12-30 |
| EP2242362A1 (en) | 2010-10-27 |
| JP2011520770A (ja) | 2011-07-21 |
| CA2712604A1 (en) | 2009-07-30 |
| BRPI0906785A2 (pt) | 2015-07-14 |
| AU2009206588A1 (en) | 2009-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010007948A (es) | Inhibidores de proteinas de apoptosis. | |
| EA201290184A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
| MX2009006706A (es) | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
| MX2009007104A (es) | Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina. | |
| UA110612C2 (uk) | Похідні 1-аміно-2-циклопропілетилборонової кислоти | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
| EA201290183A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
| PH12014500053A1 (en) | Proteasome inhibitors | |
| PH12015501964B1 (en) | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
| MY166653A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
| MX2007003013A (es) | Amidas biciclicas como inhibidores de cinasa. | |
| EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
| NZ719905A (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MY164581A (en) | Purin derivatives for use in the treatment of fab-related diseases | |
| EA200901138A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
| GEP20125511B (en) | Mapk/erk kinase inhibitors | |
| TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
| MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| MX2009006327A (es) | Compuestos heterociclicos y metodos de uso de los mismos. | |
| UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
| WO2009062576A3 (en) | Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same | |
| GB201302704D0 (en) | Therapeutic compounds | |
| MA32183B1 (fr) | Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt | |
| EA201792341A1 (ru) | Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |